Lower midbrain dopamine transporter availability in depressed patients: Report from high-resolution PET imaging

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Imaging

Background:

• Reduced presynaptic dopamine neurotransmission is a proposed mechanism in major depressive disorder (MDD).
• Previous molecular imaging studies on dopamine transporter (DAT) availability in MDD have yielded inconsistent results, often focusing solely on the striatum.
• Extra-striatal regions, crucial for dopamine pathways, have been under-investigated in MDD.

Purpose of the Study:

• To investigate striatal and extra-striatal dopamine transporter (DAT) availability in patients with major depressive disorder (MDD).
• To compare DAT availability in depressed patients versus healthy controls using high-resolution Positron Emission Tomography (PET).
• To explore the role of dopamine dysfunction in the pathophysiology of depression.

Main Methods:

• Utilized a database of high-resolution Positron Emission Tomography (PET) images with the selective radiotracer [¹¹C]PE2I.
• Assessed striatal and extra-striatal DAT availability in eight patients treated for depression and twenty-four healthy controls.
• Employed statistical parametric mapping and voxel-based analyses for PET image analysis.

Main Results:

• Significantly lower DAT availability was detected in the superior midbrain (including the ventral tegmental area and substantia nigra) of depressed patients compared to controls.
• A similar reduction in DAT availability was observed in the right dorsal putamen of depressed patients.
• Statistical power was limited, capable of detecting only large effect sizes due to the small patient sample.

Conclusions:

• The findings support the hypothesis that reduced presynaptic dopamine function contributes to the pathophysiology of major depressive disorder (MDD).
• Investigating extra-striatal dopamine function is crucial for a comprehensive understanding of depression.
• This study highlights the potential of molecular imaging to reveal regional dopamine deficits in MDD.